GlassScriptPhysician profile
Sidney J Goldfarb
NPI 1093776916
$1,283.70
in general payments reported to CMS, 2019-2025
12 companies · $15.00 in 2025
The $15.00 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $200 · 2021: $583 · 2023: $79.35 · 2025: $15.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $79.35 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $79.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $586.00 | 2019-2023 | |
| Abbvie INC. | $264.26 | 2019-2021 | |
| Allergan, INC. | $125.01 | 2019 | |
| Urovant Sciences INC | $119.13 | 2021 | |
| Pfizer INC. | $83.34 | 2019-2021 | |
| Si-Bone, INC. | $23.43 | 2021 | |
| Becton, Dickinson and Company | $15.00 | 2025 | Bard X-Force Balloon Dilation Catheter |
| Avadel Specialty Pharmaceuticals, LLC | $14.18 | 2019 | |
| Dentsply Ih INC. | $13.85 | 2021 | |
| Janssen Biotech, INC. | $13.29 | 2019 | |
| Myovant Sciences INC. | $13.13 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.